Eli Lilly's New Obesity Treatment Achieves 23% Weight Loss in Diabetic Patients
Eli Lilly's latest experimental treatment, which combines eloralintide and Mounjaro, has shown promising results in a recent study, achieving an average weight loss of 23% among participants with type 2 diabetes. This significant finding may enhance Lilly's position in the competitive obesity and diabetes treatment market, particularly against rival Novo Nordisk. The study involved 367 adults who were randomized to receive either a placebo, eloralintide alone, tirzepatide alone, or various combinations of the two drugs. The results were presented at the European Association for the Study of Diabetes (EASD) meeting in Milan. Participants receiving the highest dose of the combination lost an average of 54 pounds over 48 weeks, with their A1C levels, a measure of average blood sugar, decreasing by 2.9 percentage points from a baseline of 8.1%. Remarkably, up to three-quarters of the participants reached normal blood sugar levels. Ken Custer, president of Lilly's cardiometabolic unit, expressed optimism about the study's outcomes, stating that it sets a new benchmark for weight loss treatments, although he cautioned against direct comparisons with other studies. Lilly's stock saw a modest increase following the announcement, reflecting investor interest in the potential of this new treatment. The combination therapy, dubbed EloraTZP, works by targeting multiple pathways related to appetite and blood sugar regulation. Eloralintide mimics amylin, a hormone that helps regulate digestion and signals feelings of fullness, while tirzepatide activates two gut hormone receptors, GIP and GLP-1. This multifaceted approach is designed to enhance the efficacy of weight loss in individuals with diabetes, who typically face greater challenges in achieving weight loss. However, the study also highlighted some concerns, as 27% of participants at the highest dose discontinued treatment due to side effects, primarily gastrointestinal issues such as nausea. The discontinuation rates due to adverse events varied across the different treatment arms, with higher rates observed in those receiving the combination therapy compared to tirzepatide alone. Analysts noted that a more gradual titration of the dosing regimen might improve patient adherence while maintaining efficacy. The competitive landscape for obesity treatments is intensifying, particularly as Novo Nordisk's CagriSema, a combination of cagrilintide and semaglutide, has faced setbacks in proving its effectiveness against Lilly's Mounjaro. Lilly plans to initiate late-stage studies of the new combination therapy by the end of the year, aiming to streamline the treatment into a single co-formulated injection, which could further enhance patient compliance and outcomes. As the obesity treatment market evolves, the implications of these findings could significantly influence treatment options for individuals with diabetes and obesity.




